Radiotherapy as a primary treatment modality for a young man with a primary urethral plasmacytoma: case report and literature review.

Bibliographic Details
Title: Radiotherapy as a primary treatment modality for a young man with a primary urethral plasmacytoma: case report and literature review.
Authors: Lim, Soo How, Poh, Tian Er, Wee, Hong Chin, Awang Basry, Nur Shazwaniza Binti, Tajul Arifin, Mohd Syazwan Bin, Yong, Kar Ying
Source: Frontiers in Oncology; 2025, p1-5, 5p
Subject Terms: PLASMA cells, PLASMACYTOMA, CELL tumors, RETENTION of urine, MULTIPLE myeloma
Abstract: Primary urethral plasmacytoma is an extremely rare form of solitary plasmacytoma, with only 10 cases reported in the literature. It involves localized clonal proliferation of plasma cells without systemic disease. This report presents a 29-year-old man with acute urinary retention and a urethral mass, confirmed as solitary plasmacytoma. The patient was treated with 45 Gy of local radiotherapy, resulting in complete tumor resolution without recurrence or progression at a 2-year follow-up. Given its rarity, treatment strategies for primary urethral plasmacytoma are not well-defined. Radiotherapy is preferred over surgery in young patients due to the radiosensitivity of plasma cell tumors and its ability to preserve sexual and urinary function. A review of previous cases treated with radiotherapy alone, using doses of 40–50 Gy, showed favorable outcomes with no recurrences reported over follow-up periods ranging from 6 months to 12 years. Only one patient experienced minor long-term complications. This report highlights the effectiveness of radiotherapy as a primary modality for managing primary urethral plasmacytoma, offering excellent local control while preserving organ function. Individualized treatment plans should consider patient age, fertility concerns, and tumor characteristics. Further research is necessary to optimize treatment protocols and long-term surveillance strategies due to the potential risk of recurrence or progression to multiple myeloma. [ABSTRACT FROM AUTHOR]
Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
More Details
ISSN:2234943X
DOI:10.3389/fonc.2025.1528536
Published in:Frontiers in Oncology
Language:English